Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approval of supplemental NDA for for Iclusig (ponatinb) in adult patients with newly diagnosed Ph+ ALL – Takeda

Written by | 29 Mar 2024

Takeda announced that the FDA has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.